Addressing the Barriers to Pediatric Drug Development: Workshop Summary

Excerpt

The purpose of the workshop was to identify barriers to the development and testing of drugs for pediatric populations, as well as ways in which the system can be improved to facilitate better treatments for children. The Forum invited representatives from the U.S. Food and Drug Administration (FDA), the National Institutes of Health, the American Academy of Pediatrics, the pharmaceutical industry, academia, and several patient advocacy groups to discuss: the current regulatory framework; current challenges in prescribing and developing drugs for children; models for enhancing pediatric drug development; and challenges and opportunities for the future.